Lorem Ipsum Dolor Sit Amet, Consectetur Adipiscing Elit
Lorem Ipsum Dolor Sit Amet, Consectetur Adipiscing Elit
RICOH's Digital Micro Factory: Sustainable Innovation in the Apparel Industry
UNDER ARMOUR INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Under Arm
ADTRAN 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Dead
CV SCIENCES INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CV Science
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Live Nation Entertainment, Inc. and Encourages Investors with Lo
Global Sexually Transmitted Disease (STD) Testing Market 2019-2023 | Evolving Opportunities with Abbott Laboratories and bioMérieux SA | Technavio
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Amdocs Limited Investors (DOX)
Santa Clara University Sends Early Admission Decisions After Record Number of Applications
-
Tutor Perini Statement on Jury's Decision in SR 99 Alaskan Way Viaduct Replacement Project Trial
LOS ANGELES--(BUSINESS WIRE)--Tutor Perini Corporation (NYSE: TPC) (the “Company”), a leading civil, building and specialty construction company, released the statement below in reaction to a jury verdict in favor of the plaintiff in the case of Washington State Department of Transportation v. Seattle Tunnel Partners (“STP”) et. al., a trial conducted in the Thurston County District Court in the state of Washington. The trial dealt with various disputed claims related to the SR 99 Alaskan Way Viaduct Replacement Project, which was constructed by STP, a joint venture between the Company and Dragados USA, Inc. Tutor Perini is disappointed with the jury’s decision and will appeal the verdict in this case, which conflicts directly with the findings of an independent Dispute Review Board’s (“DRB”) proceedings that were conducted over the course of the project, including a key finding by the DRB that the steel pipe casing unexpectedly encountered by the tunnel boring machine constituted a “differing site condition.” Over the past several years, Tutor Perini has consistently asserted that the Company (through its 45% participation in STP) is owed compensation for substantial costs incurred as a result of that unexpected encounter and the subsequent delays and repairs that ensued. The Company is reviewing today’s decision to evaluate any potential financial impact on the Company and will provide any required disclosure once that evaluation has been completed. A separate court trial in King County, Washington pertaining to the pursuit of associated claims against insurance policies that covered the project is expected to occur in the latter part of next year or in 2021. About Tutor Perini Corporation Tutor Perini Corporation is a leading civil, building and specialty construction company offering diversified general contracting and design-build services to private clients and public agencies throughout the world. We have provided construction services since 1894 and have established a strong reputation within our markets by executing large, complex projects on time and within budget while adhering to strict quality control measures. Contacts Tutor Perini Corporation Jorge Casado, 818-362-8391 Vice President, Investor Relations and Corporate Communications www.tutorperini.com
-
Global Genetic Testing Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Agilent Technologies Inc. | Technavio
LONDON--(BUSINESS WIRE)--#genetictesting--The global genetic testing market is expected to grow by USD 4.86 billion during 2020-2024, according to the latest market research report by Technavio, progressing at a CAGR of over 12% during the forecast period. The growth of the market can be attributed to factors such as the prevalence of genetic diseases and disorders, increasing approvals of advanced genetic testing products, and affordability due to the reduction in the cost of genetic testing. Request a free sample report The market research report segments the genetic testing market by product (equipment and consumables), by geography (Asia, Europe, North America, and ROW), end-users (clinical diagnostic laboratories, hospitals, and biopharmaceutical companies and research centers), and application (predictive and diagnostic testing, prenatal, newborn, and preimplantation testing; pharmacogenomic testing; and forensic, relationship, and ancestry testing). https://www.technavio.com/report/genetic-testing-market-industry-analysis Genetic Testing Product Outlook (Revenue, USD Billion, 2020-2024) Equipment Consumables The market will witness a maximum demand for equipment over the forecast period. The United Nations Sustainable Development Goals has set the target to end infectious diseases such as tuberculosis by 2030. Such initiatives are promoting the upgradation of diagnostic infrastructures with modern and efficient genetic diagnostic equipment such as RT-PCRs and automated analyzers. Vendors are also constantly expanding their product portfolios with advanced automated DNA analyzers to stay competitive in the market. QIAxcel Advanced System from QIAGEN is one such example. Many such factors are fueling the growth of the equipment segment. Genetic Testing Regional Outlook (Revenue, USD Billion, 2020-2024) Asia Europe North America ROW The North American region led the genetic testing market in 2019, followed by Europe, Asia, and ROW. Over the forecast period, the North American region is expected to retain its position as the largest market for genetic testing. This is due to a growing emphasis on early disease diagnosis, significant rise in commercial approvals for advanced genetic testing products, and the increasing adoption of pharmacogenetic testing in the region. The region has a strong base of established vendors that are consistently focusing on offering advanced products such as chromosome enumeration probes by Abbott Laboratories, Next Generation Sequencing by Agilent Technologies, and others. Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Major Five Genetic Testing Companies: Abbott Laboratories, Agilent Technologies Inc., bioMérieux SA, Bio-Rad Laboratories Inc., and F. Hoffmann-La Roche Ltd. are among the vendors who have a strong position in the global market. Abbott Laboratories Abbott Laboratories operates its business across various segments such as Established Pharmaceuticals, Nutritionals, Diagnostics, Cardiovascular and Neuromodulation, and Other. Some of the key offerings of the company include Chromosome enumeration probes, FISH accessories, Postnatal, and Prenatal. Agilent Technologies Inc. Agilent Technologies Inc. operates the business across segments such as Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. Some of the key offerings of the company include Next Generation sequencing, FISH Probes, PCR, CRISPR/Cas9, and Oligonucleotide Libraries. bioMérieux SA bioMérieux SA operates its business in the In-vitro diagnostics segment. The company offerings cover instruments/devices and kits used for extraction, amplification, and detection under its molecular diagnostics product category. Some of the significant products include Argene, NucliSENS easyMag, NucliSENS easyQ, DiversiLab, and Filmarray. Bio-Rad Laboratories Inc. Bio-Rad Laboratories Inc. operates its business through the Life Science and Clinical Diagnostics segments. The company offers a wide range of genetic solutions under its Genomics product category. Some of the key offerings of the company include PCR Systems, lncRNA RT-qPCR Workflow, PCR Reagents Consumables & Accessories, Nucleic Acid Sample Preparation, Nucleic Acid Electrophoresis & Blotting, and In Vitro Diagnostics (IVD)-based genetic testing products. F. Hoffmann-La Roche Ltd. F. Hoffmann-La Roche Ltd. operates the business across the Pharmaceuticals and Diagnostics segments. The company offers a wide range of diagnostic testing systems and assays, gene sequencing assays, kits, reagents, and systems. Some of the key offerings of the company include COBAS TaqMan System, cobas 4800 System, cobas HIV-1, COBAS AmpliPrep, NAVIFY Mutation Profiler, AVENIO NGS Oncology Assays, AVENIO Tumor Tissue Analysis Kits, HEAT-Seq Oncology Panel, and others. Genetic Testing End-User Outlook (Revenue, USD Billion, 2020-2024) Hospitals Biopharmaceutical companies and research centers Genetic Testing Application Outlook (Revenue, USD Billion, 2020-2024) Predictive and diagnostic testing Prenatal, newborn, and preimplantation testing Pharmacogenomic testing Forensic, relationship, and ancestry testing About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: media@technavio.comWebsite: https://www.technavio.com
-
Susan G. Komen® Study Confirms Treatment Options for HER2-negative Patients With BRCA1/2 Mutations
Results of INFORM Study Released at San Antonio Breast Cancer Symposium SAN ANTONIO--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, today welcomed the results of the INFORM trial that were announced at the 2019 San Antonio Breast Cancer Symposium. The Komen-funded INFORM trial led by Dr. Nadine Tung shows that HER2-negative patients with a BRCA1/2 gene mutation have multiple effective treatment options. Dr. Tung and colleagues sought to determine if cisplatin chemotherapy is a more effective treatment than the current, standard of care treatment, chemotherapy with doxorubicin and cyclophosphamide (commonly referred to as “AC”). Prior retrospective studies, which looked at treatment that has already occurred as part of the study, had indicated that cisplatin chemotherapy might work better than AC. The INFORM clinical trial was the first prospective study, or a study that evaluates treatment moving forward, to actually test this idea. “For HER2-negative breast cancer patients with BRCA1/2 mutations, the INFORM trial confirmed that cisplatin chemotherapy is not more effective than standard chemotherapy with doxorubicin and cyclophosphamide. The results suggest that BRCA carriers may respond to both types of chemotherapy – which kill cancer cells by damaging DNA – giving them multiple options to treat their cancer,” said Dr. Tung. Prospective studies are essential for improving clinical practice. She added, “Funding from Susan G. Komen was essential for this work.” Funded in part by a Komen Opportunity Grant, the INFORM trial is also part of the Translational Breast Cancer Research Consortium (TBCRC), which has been supported by Komen for more than 10 years. Victoria Wolodzko, senior vice president of Mission at Susan G. Komen, added, “Patients with BRCA mutations face many challenges, especially those in rural or underserved areas. This work confirms that physicians have more options for these patients. Patients won’t need to wait for a specific treatment to ensure they are getting the best care no matter where they live.” About Susan G. Komen® Susan G. Komen® is the world’s leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow’s cures. Contacts Sean Tuffnell Susan G. Komen® 972-855-4382 press@komen.org
-
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the 2019 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The presentation entitled, “Effect of prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2-positive early-stage breast cancer: Phase II CONTROL trial,” will be displayed at a poster session on December 13 at 5:00 p.m. CST. A full copy of the poster is available on the Puma Biotechnology website. Neratinib was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and is marketed in the United States as NERLYNX® (neratinib) tablets. The main adverse event seen to date in clinical trials of neratinib is diarrhea and, more specifically, grade 3 diarrhea. In the Phase III ExteNET trial of neratinib as extended adjuvant treatment of HER2-positive early stage breast cancer that has previously been treated with adjuvant Herceptin, prophylactic use of anti-diarrheal medications was not mandatory. In the trial, 95.4% of the patients experienced all grade diarrhea and 39.8% of the patients experienced grade 3 or higher diarrhea (there was one event of grade 4 diarrhea). The median cumulative duration of grade 3 diarrhea in the ExteNET trial was 5 days and 16.8% of patients who received neratinib in the ExteNET trial discontinued the drug due to diarrhea. The CONTROL trial is an international, open-label, Phase II study investigating the use of antidiarrheal prophylaxis or dose escalation in the reduction of neratinib-associated diarrhea that has a primary endpoint of the incidence of grade 3 diarrhea. In the CONTROL trial, patients with HER2-positive early stage breast cancer who had completed trastuzumab-based adjuvant therapy received neratinib daily for a period of one year. The trial initially tested high dose loperamide prophylaxis given for the first 2 cycles (56 days) of treatment (12 mg on days 1-14, 8 mg on days 15-56 and as needed thereafter). The CONTROL trial was then expanded to include four additional cohorts. One cohort received the combination of loperamide and budesonide, the second cohort received the combination of loperamide plus colestipol, the third cohort received colestipol plus loperamide as needed and the fourth cohort did not use any antidiarrheal drugs as mandatory prophylaxis but instead used a dose escalation during the first month of neratinib treatment. Budesonide is a locally acting corticosteroid that Puma believes targets the inflammation identified in a preclinical model of neratinib-induced diarrhea and colestipol is a bile acid sequestrant that Puma believes targets potential bile acid malabsorption that could result from such inflammation. The dose escalation involved treating with neratinib at 120 mg per day for the first week, 160 mg per week for the second week and 240 mg per week starting at week 3 and until the end of treatment. The interim analysis of the CONTROL trial presented in the poster included a total of 137 patients who received neratinib plus loperamide prophylaxis, 64 patients who received neratinib plus loperamide prophylaxis for 2 cycles and budesonide for 1 cycle, 136 patients who received neratinib plus loperamide prophylaxis for 1 cycle and colestipol for 1 cycle, 104 patients who received colestipol for 1 cycle and loperamide as needed and 60 patients who received the dose escalation regimen of neratinib. The results of the trial showed that the incidence of grade 3 diarrhea for the 137 patients who received the loperamide prophylaxis was 31% and that for the 137 patients in this cohort, 20% discontinued neratinib due to diarrhea. The median cumulative duration of grade 3 diarrhea was 3 days. For the 64 patients who received the combination of loperamide plus budesonide, the results of the trial showed that the incidence of grade 3 diarrhea was 28% and that for the 64 patients in this cohort, 11% discontinued neratinib due to diarrhea. The median cumulative duration of grade 3 diarrhea was 2.5 days. For the 136 patients who received the combination of loperamide plus colestipol, the results of the trial showed that the incidence of grade 3 diarrhea was 21% and that for the 136 patients in this cohort, 4% discontinued neratinib due to diarrhea. The median cumulative duration of grade 3 diarrhea was 3.5 days. For the 104 patients who received colestipol and loperamide as needed, the results of the trial showed that the incidence of grade 3 diarrhea was 34% and that for the 104 patients in this cohort, 8% discontinued neratinib due to diarrhea. The median cumulative duration of grade 3 diarrhea was 3 days. For the 60 patients who received no antidiarrheal drugs as mandatory prophylaxis and dose escalation of neratinib in the first month, the results of the trial showed that the incidence of grade 3 diarrhea was 15% and that for the 60 patients in this cohort, 3% discontinued neratinib due to diarrhea. The median cumulative duration of grade 3 diarrhea was 2 days. Further information is provided in Table 1 below: Table 1: Incidence of Treatment-Emergent Diarrhea Neratinib dose Budesonide + Colestipol + Colestipol + escalation + Loperamide loperamide loperamide loperamide prn loperamide prn (n=137) (n=64) (n=136) (n=104) (n=60) Treatment-emergent diarrhea incidence, n (%) No diarrhea 28 (20) 9 (14) 23 (17) 5 (5) 2 (3) Grade 1 33 (24) 16 (25) 38 (28) 33 (32) 24 (40) Grade 2 34 (25) 21 (33) 47 (35) 31 (30) 25 (42) Grade 3 42 (31) 18 (28) 28 (21) 35 (34) 9 (15) Grade 4 0 0 0 0 0 Diarrhea leading to discontinuation 28 (20.4) 7 (10.9) 5 (3.7) 8 (7.7) 2 (3.3) Hospitalization (due to diarrhea) 2 (1.5) 0 0 0 0 Discontinuation of study (any cause) 61 (44.5) 13 (20.3) 39 (28.7) 29 (27.9) 12 (20.0) Note: Each patient was counted only once in the highest grade category. No Grade 4 events reported in the CONTROL study. Carlos H. Barcenas, MD, MS, Associate Professor in the Department of Breast Medical Oncology of The University of Texas MD Anderson Cancer Center, said, “We are pleased to see the maturation of the data supporting observations of a reduction in incidence, severity and duration of neratinib-associated diarrhea with loperamide prophylaxis, loperamide plus budesonide prophylaxis or the loperamide plus colestipol prophylaxis. Along with the continued reduction in the incidence and severity of grade 3 diarrhea with neratinib, diarrhea appears to be early onset, acute, self-limiting and manageable. Not only does the addition of budesonide or colestipol to loperamide prophylaxis appear to greatly improve the tolerability of neratinib, the dose escalation regimen appears as another promising option since there is no mandatory prophylaxis.” Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology, said, “We are pleased to note that the dose-escalation cohort of our CONTROL trial continues to show a marked improvement in the incidence of grade 3 diarrhea and related discontinuation of therapy. We remain committed to improving the tolerability of neratinib in early stage breast cancer patients.” About HER2-Positive Breast Cancer Approximately 20% to 25% of breast cancer tumors over-express the HER2 protein. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery, up to 25% of patients treated with trastuzumab experience recurrence. IMPORTANT SAFETY INFORMATION NERLYNX® (neratinib) tablets, for oral use INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. CONTRAINDICATIONS: None WARNINGS AND PRECAUTIONS: Diarrhea: Aggressively manage diarrhea occurring despite recommended prophylaxis with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold NERLYNX in patients experiencing severe and/or persistent diarrhea. Permanently discontinue NERLYNX in patients experiencing Grade 4 diarrhea or Grade ≥ 2 diarrhea that occurs after maximal dose reduction. Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities. Embryo-Fetal Toxicity: NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ADVERSE REACTIONS: The most common adverse reactions (≥ 5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, weight decreased and urinary tract infection. To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and www.NERLYNX.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS: Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors. When patients require gastric acid reducing agents, use an H2-receptor antagonist or antacid. Separate NERLYNX by at least 3 hours with antacids. Separate NERLYNX by at least 2 hours before or 10 hours after H2-receptor antagonists. Strong or moderate CYP3A4 inhibitors: Avoid concomitant use. Strong or moderate CYP3A4 inducers: Avoid concomitant use. P-glycoprotein (P-gp) substrates: Monitor for adverse reactions of narrow therapeutic agents that are P-gp substrates when used concomitantly with NERLYNX. USE IN SPECIFIC POPULATIONS: Lactation: Advise women not to breastfeed. Please see Full Prescribing Information for additional safety information. The recommended dose of NERLYNX is 240 mg (six 40 mg tablets) given orally once daily with food, continuously for one year. Antidiarrheal prophylaxis should be initiated with the first dose of NERLYNX and continued during the first 2 months (56 days) of treatment and as needed thereafter. To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at www.NERLYNX.com or 1-855-816-5421. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. NERLYNX was granted marketing authorization by the European Commission in August 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc. Further information about Puma Biotechnology can be found at www.pumabiotechnology.com. Contacts Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500 info@pumabiotechnology.comir@pumabiotechnology.com David Schull or Maggie Beller, Russo Partners, +1-212-845-4200 david.schull@russopartnersllc.commaggie.beller@russopartnersllc.com
-
Global Automotive ADAS Aftermarket 2020-2024 | Growing Online Purchase of Aftermarket ADAS to Boost Growth | Technavio
LONDON--(BUSINESS WIRE)--#automotiveADAS--The global automotive ADAS aftermarket is expected to post a CAGR of 9% during the period 2020-2024, according to the latest market research report by Technavio. Request a free sample report Growing emphasis on automotive safety among customers is one of the critical factors leading to the growth of global automotive ADAS aftermarket. ADAS reduces vehicle crashes and fatalities caused due to factors such as drowsiness, loss of concentration, and fatigue among drivers. As a result, the demand for several ADAS technologies such as backup cameras, BSD, LDWS, and FCWS is increasing, particularly, as an aftermarket automotive fitment. Furthermore, the demand for customized products from consumers is also encouraging manufacturers to offer tailor-made ADAS aftermarket solutions, which will further drive market growth during the forecast period. To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40268 As per Technavio, the growing online purchase of aftermarket ADAS will have a positive impact on the market and contribute to its growth significantly over the forecast period. This research report also analyzes other significant trends and market drivers that will affect market growth over 2020-2024. Global Automotive ADAS Aftermarket: Growing Online Purchase of Aftermarket ADAS E-retailing has emerged as one of the critical platforms for customers to purchase automotive products conveniently. Consumers from remote regions can easily access e-commerce platforms to make online purchases of aftermarket ADAS. E-retailing in the automotive aftermarket further allows buyers to compare prices of automotive products from different brands and make informed purchase decisions. The availability of online platforms has also encouraged vendors to increase their product visibility by offering their aftermarket ADAS products on popular e-commerce portals. Other manufacturers such as Brandmotion and Garmin have their dedicated online portals, which allow customers to purchase their products directly from the vendor. “Stringent regulations to promote the adoption of ADAS and development of aftermarket ADAS for commercial vehicles will boost the market growth during the forecast period,” says a senior analyst at Technavio. Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform Global Automotive ADAS Aftermarket: Segmentation Analysis This market report segments the global automotive ADAS aftermarket by technology (passive car assists, FCWS and LDWS, and others) and geography (APAC, Europe, MEA, North America, and South America). North America led the automotive ADAS aftermarket share in 2019, followed by Europe, APAC, South America, and MEA, respectively. Factors such as the strong presence of prominent vendors and high consumer awareness about ADAS in the US are driving the region to dominate the automotive ADAS aftermarket. However, APAC is expected to witness the fastest growth in the market owing to the growing popularity of automotive ADAS in countries such as China, Japan, and South Korea. Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report Some of the key topics covered in the report include: Market Landscape Market ecosystem Market characteristics Market segmentation analysis Market Sizing Market definition Market size and forecast Five Forces Analysis Market Segmentation Customer Landscape Geographical Segmentation Geographic comparison Key leading countries Market Drivers Market Challenges Market Trends Vendor Landscape Landscape disruption Competitive scenario Vendor Analysis Vendors covered Vendor classification Market positioning of vendors About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: media@technavio.comWebsite: https://www.technavio.com/
-
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Live Nation Entertainment, Inc. – LYV
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Live Nation Entertainment, Inc. (NYSE: LYV) resulting from allegations that Live Nation may have issued materially misleading business information to the investing public. On December 13, 2019, the Wall Street Journal reported that the U.S. Department of Justice (“DOJ”) was preparing to take legal action against Live Nation based on allegations that the company sought to “strong-arm” concert venues into using its market-dominant Ticketmaster subsidiary. Such efforts would violate the terms of a settlement agreement that Live Nation and Ticketmaster reached with the government in 2010 as a condition of their merger. Under that agreement, the DOJ allowed the companies to combine, but required them to abide by conditions meant to preserve competition in the music and ticketing industries. As a result of this news, Live Nation’s share price fell $5.09 or 7.3% to close at 64.34 on December 13, 2019. Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Live Nation investors. If you purchased shares of Live Nation please visit the firm’s website at http://www.rosenlegal.com/cases-register-1741.html to join the class action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contacts Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.compkim@rosenlegal.comcases@rosenlegal.comwww.rosenlegal.com
-
Kia Ora Auckland! Air Canada Inaugurates Seasonal Service From Vancouver
VANCOUVER, British Columbia and AUCKLAND, New Zealand, Dec. 14, 2019 /PRNewswire/ -- Air Canada's inaugural flight AC51, 787 Dreamliner service which departed last night from Vancouver has arrived in Auckland, marking the carrier's launch of seasonal service between Canada and New Zealand. Flights operate four times weekly until the end of March 2020. "We are excited to launch our newest South Pacific route to Auckland which offers additional opportunities for North Americans travelling to enjoy New Zealand's summer season, and for New Zealanders travelling for a Canadian winter vacation. Our Auckland flights are timed to conveniently connect at our extensive Vancouver trans-Pacific hub to and from a multitude of non-stop destinations throughout North America including New York-Newark," said Mark Galardo, Vice President, Network Planning at Air Canada. "We are very excited to welcome this new service from Air Canada which further connects Vancouver to Auckland using the amazing Dreamliner aircraft," said Craig Richmond, President and CEO, Vancouver Airport Authority. "This addition to Air Canada's growing network at Vancouver International Airport will not only open up more business and travel opportunities in Canada and New Zealand, it will also facilitate valuable connecting traffic between the two airports. We appreciate Air Canada's continued commitment to utilizing Vancouver as their trans-Pacific hub." "We're proud of the contribution this new service will make to growing travel and trade between the two countries. The seamless connections Air Canada provides through its hub in Vancouver will further promote a growing market. In 2018 alone, Canadians choosing to holiday in New Zealand grew by 6.7 percent to 70,000 visitors. Similarly, New Zealand visitor numbers grew by an impressive 12 percent with 34,000 people visiting Canada during the same period," said Scott Tasker, General Manager of Aeronautical Commercial at Auckland Airport. "Canada is one of New Zealand's closest international partners. The new Air Canada non-stop service between Vancouver and Auckland will contribute to strengthening our close connections, further increasing our people-to-people links and tourism links," said Amy Tisdall, New Zealand's chargée d'affaires. "I'm thrilled that Air Canada will be offering direct flights from Auckland to Vancouver. B.C. is a sought-after destination for international visitors, with Vancouver International Airport as the gateway to exploring our beautiful province. And now, with the HSBC Canada Sevens set to take place in Vancouver for another four years, this is the perfect time for rugby fans from around the world to visit B.C. To our friends in New Zealand, we say Kia Ora!" said Lisa Beare, British Columbia's Minister of Tourism, Arts and Culture. Air Canada's state-of-the-art Boeing 787-8* Dreamliners feature 20 Signature Class lie-flat seats, 21 Premium Economy and 214 Economy Class seats with upgraded in-flight entertainment at every seat throughout the aircraft. All Air Canada flights provide for Aeroplan accumulation and redemption and, for eligible customers, access to priority services, Maple Leaf Lounges and other benefits. Flight Departs Arrives Days of Week AC51 Vancouver (YVR) 23:45 Auckland (AKL) 11:05 + 2 days Mon, Tue, Thur, Sat AC52 Auckland (AKL) 14:30 Vancouver (YVR) 06:30 Mon, Wed, Thur, Sat Air Canada's Vancouver-Auckland service is the latest of three new international routes the carrier just inaugurated, following Air Canada's launch of the only flights from Montreal-Sao Paulo on Dec. 11 and from Toronto-Quito on Dec. 8. *Air Canada's inaugural flight operated with a Boeing 787-9 exceptionally About Air Canada Air Canada is Canada's largest domestic and international airline serving nearly 220 airports on six continents. Canada's flag carrier is among the 20 largest airlines in the world and in 2018 served nearly 51 million customers. Air Canada provides scheduled passenger service directly to 62 airports in Canada, 53 in the United States and 101 in Europe, the Middle East, Africa, Asia, Australia, the Caribbean, Mexico, Central America and South America. Air Canada is a founding member of Star Alliance, the world's most comprehensive air transportation network serving 1,250 airports in 195 countries. Air Canada is the only international network carrier in North America to receive a Four-Star ranking according to independent U.K. research firm Skytrax, which also named Air Canada the 2019 Best Airline in North America. For more information, please visit: aircanada.com/media, follow @AirCanada on Twitter and join Air Canada on Facebook. Internet: aircanada.com/media Media Resources: Photos Videos Articles For further information: media@aircanada.ca Related Links :https://www.aircanada.com/media
-
Passport Health Continues Expansion, Opening Its First UK Clinic
PHOENIX--(BUSINESS WIRE)--Passport Health, the world’s largest provider of travel medicine, announces its international expansion to London, England. This marks the beginning of an international expansion plan put in place by CEO David Tedesco. Passport Health dominates the travel medicine market, with over 300 clinics network-wide, which includes 30+ clinics in Mexico and Canada. The London office will be the first outside of North America, providing travel health, corporate wellness and other services to London’s avid international travel community. Started in a single office over 25 years ago in Baltimore, MD by Fran Lessans, Passport Health became a franchise organization spanning the United States. From there, the organization expanded into Canada and Mexico. After receiving numerous online inquiries from London, Tedesco began to take a look at expanding into the European market. “Entering the UK is a critical milestone for our business,” stated David Tedesco, Passport Health Chairman. “While we began this journey in North America, it is our vision to help international travelers around the world, and this was an important first step. ” Ranked 6th in the world for travel readiness by the World Economic Forum, London provided a large travel market and no language barrier, making it a prime expansion location for Passport Health. The company will offer the same high-touch service in its new London clinic that has been foundational to its North American success, including destination-specific consultations as well as travel vaccinations and medicine to ensure those traveling outside the UK have a safe and healthy trip. Passport Health plans to continue its expansion, both domestically and internationally, to ensure international travelers have the education, vaccinations and medications they need to travel well. Passport Health is an Outlier company. About Passport Health Passport Health is the largest provider of travel medicine and immunization services, with over 300 clinics and a dedicated team of highly trained nurses who are travel wellness experts. With more than 25 years of experience, a commitment to first-class medical care, and rigorously trained medical staff, Passport Health sets the immunization industry standard. Passport Health’s core services have grown from travel medicine to include passport and visa services, on-site flu clinics, specialty physical exams, routine immunizations, and vaccination record management for the public and private sector. Passport Health is an Outlier company. Contacts Melissa Marchwick, CMO mmarchwich@outlier.com310-684-2681
-
Ellington Residential Mortgage REIT Announces Dividend for the Fourth Quarter of 2019
OLD GREENWICH, Conn.--(BUSINESS WIRE)--Ellington Residential Mortgage REIT (NYSE:EARN) (the "Company") today announced that its Board of Trustees has declared a dividend for the fourth quarter of 2019 of $0.28 per share, payable on January 27, 2020, to common shareholders of record as of December 31, 2019. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical in nature and can be identified by words such as "anticipate," "estimate," "will," "should," "may," "expect," "project," "believe," "intend," "seek," "plan" and similar expressions or their negative forms, or by references to strategy, plans, or intentions. For example, our results can fluctuate from month to month and quarter to quarter depending on a variety of factors, some of which are beyond our control and/or difficult to predict, including, without limitation, changes in interest rates, changes in default rates and prepayment speeds, and other changes in market and economic conditions. Our actual results may differ from our beliefs, expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Furthermore, forward-looking statements are subject to risks and uncertainties, including, among other things, those described under Item 1A to the Company's Annual Report on Form 10-K filed on March 8, 2019, which can be accessed through the link to our SEC filings under "For Our Shareholders" on our website (www.earnreit.com) or at the SEC's website (www.sec.gov). Other risks, uncertainties, and factors that could cause actual results to differ materially from those projected may be described from time to time in reports we file with the SEC, including reports on Forms 10-Q, 10-K and 8-K. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. About Ellington Residential Mortgage REIT Ellington Residential Mortgage REIT is a mortgage real estate investment trust that specializes in acquiring, investing in and managing residential mortgage- and real estate-related assets, with a primary focus on residential mortgage-backed securities for which the principal and interest payments are guaranteed by a U.S. government agency or a U.S. government-sponsored enterprise. Ellington Residential Mortgage REIT is externally managed and advised by Ellington Residential Mortgage Management LLC, an affiliate of Ellington Management Group, L.L.C. Contacts Investors: Ellington Residential Mortgage REIT Investor Relations (203) 409-3773 info@earnreit.comor Media: Amanda Klein or Kevin FitzGerald Gasthalter & Co. for Ellington Residential Mortgage REIT (212) 257-4170 Ellington@gasthalter.com
-
Fairholme Funds, Inc. December 2019 Dividend Distributions
MIAMI--(BUSINESS WIRE)--FAIRHOLME FUNDS, INC.: THE FAIRHOLME FUND (FAIRX) On December 13, 2019, the Fairholme Fund (NASDAQ: FAIRX) distributed an Ordinary Income dividend of $0.16541 per share to shareholders of record as of December 12, 2019. The Fairholme Fund’s Net Asset Value (“NAV”) was reduced by the total amount of the distribution. The Record Date, Ex-Dividend Date, Payable Date, and Cents-Per-Share are as follows: Distribution Type Record Date Ex-Dividend Date Payable Date Cents-Per-Share Ordinary Income December 12, 2019 December 13, 2019 December 13, 2019 $0.16541 Total $0.16541 THE FAIRHOLME FOCUSED INCOME FUND (FOCIX) On December 13, 2019, the Fairholme Focused Income Fund (NASDAQ: FOCIX) distributed an Ordinary Income dividend of $0.04526 per share to shareholders of record as of December 12, 2019. The Fairholme Focused Income Fund’s Net Asset Value (“NAV”) was reduced by the total amount of the distribution. The Record Date, Ex-Dividend Date, Payable Date, and Cents-Per-Share are as follows: Distribution Type Record Date Ex-Dividend Date Payable Date Cents-Per-Share Ordinary Income December 12, 2019 December 13, 2019 December 13, 2019 $0.04526 Total $0.04526 THE FAIRHOLME ALLOCATION FUND (FAAFX) On December 13, 2019, the Fairholme Allocation Fund (NASDAQ: FAAFX) distributed an Ordinary Income dividend of $0.09785 per share to shareholders of record as of December 12, 2019. The Fairholme Allocation Fund’s Net Asset Value (“NAV”) was reduced by the total amount of the distribution. The Record Date, Ex-Dividend Date, Payable Date, and Cents-Per-Share are as follows: Distribution Type Record Date Ex-Dividend Date Payable Date Cents-Per-Share Ordinary Income December 12, 2019 December 13, 2019 December 13, 2019 $0.09785 Total $0.09785 Past performance is not a guarantee of future results. Investing in the Funds involves risks including loss of principal. The Funds’ investment objectives, risks, charges, and expenses should be considered carefully before investing. The prospectus contains this and other important information about the Funds, and it may be obtained by calling Shareholder Services at (866) 202-2263 or visiting our website www.fairholmefunds.com. Read it carefully before investing. The Fairholme Fund is non-diversified, which means that The Fairholme Fund invests in a smaller number of securities when compared to more diversified funds. Therefore, The Fairholme Fund is exposed to greater individual stock volatility than a diversified fund. The Fairholme Fund also invests in foreign securities which involve greater volatility and political, economic and currency risks and differences in accounting methods. The Fairholme Fund may also invest in “special situations” to achieve its objectives. These strategies may involve greater risks than other fund strategies. The Fairholme Focused Income Fund (the “Income Fund”) is a non-diversified mutual fund, which means that the Income Fund invests in a smaller number of securities when compared to more diversified funds. This strategy exposes the Income Fund and its shareholders to greater risk of loss from adverse developments affecting portfolio companies. The Income Fund’s investments are also subject to interest rate risk, which is the risk that the value of a security will decline because of a change in general interest rates. Investments subject to interest rate risk will usually decrease in value when interest rates rise and rise in value when interest rates decline. Also, securities with long maturities typically experience a more pronounced change in value when interest rates change. Debt securities are subject to credit risk (potential default by the issuer). The Income Fund may invest without limit in lower-rated securities. Compared to higher-rated fixed income securities, lower-rated debt may entail greater risk of default and market volatility. The Fairholme Allocation Fund (the “Allocation Fund”) is a non-diversified mutual fund, which means that the Allocation Fund can invest in a smaller number of securities when compared to more diversified funds. The Allocation Fund may invest in lower-rated securities, which may have greater market risk. This strategy exposes The Allocation Fund and its shareholders to greater risk of loss from adverse developments affecting portfolio companies. The allocation of investments among the different asset classes, such as equity or fixed-income asset classes, may have a more significant effect on The Allocation Fund’s net asset value when one of these classes is performing more poorly than others. Contacts Fairholme Funds, Inc. Jodi Lin, 305-358-3000
-
MV Index Solutions Announces Quarterly Index Review Results Q4/2019
FRANKFURT, Germany--(BUSINESS WIRE)--MV Index Solutions GmbH (MVIS®) today announced the results of the quarterly MVIS index review. The following tale shows a summary of the review results for selected indices, which are licensed to underlie financial products. All review results and more details can be found on www.mvis-indices.com. The following changes will be implemented on 20 December 2019 and will become effective on the next trading day. Country/Regional Indices Additions Deletions New Count MVIS Australia Equal Weight Index 2 0 87 MVIS Australia Small-Cap Dividend Payers Index 8 0 91 MVIS Egypt Index 1 1 25 MVIS GDP Africa Index 0 2 80 MVIS Indonesia Index 0 2 41 MVIS Poland Index 1 1 25 MVIS Russia Index 0 0 26 MVIS Vietnam Index 1 1 25 Hard Assets Indices Additions Deletions New Count MVIS Australia Resources Index 0 0 25 MVIS Global Agribusiness Index 0 2 51 MVIS Global Coal Index 1 1 25 MVIS Global Junior Gold Miners Index 0 1 68 MVIS Global Oil Refiners Index 0 0 25 MVIS Global Rare Earth/Strategic Metals Index 2 2 20 MVIS Global Unconventional Oil & Gas Index 0 1 38 MVIS Global Uranium & Nuclear Energy Index 0 0 25 Sector Indices Additions Deletions New Count MVIS Australia A-REITs Index 0 0 12 MVIS Australia Banks Index 0 0 7 MVIS Global Gaming Index 0 0 42 MVIS Global Video Gaming & eSports Index 0 0 25 MVIS US Business Development Companies Index 1 1 25 MVIS US Mortgage REITs Index 0 0 25 A complete list of components and weights is available on www.mvis-indices.com. Index methodology, comprehensive index information as well as information about financial products based on MVIS Indices can also be found on our website. The next quarterly review results will be announced on 13 March 2019. Note to Editors: MV Index Solutions (MVIS®) develops, monitors and licenses the MVIS Indices, a selection of focused, investable and diversified benchmark indices. The indices are especially designed to underlie financial products. MVIS Indices cover several asset classes, including equity, fixed income markets and digital assets and are licensed to serve as underlying indices for financial products. Approximately USD 14.94 billion in assets under management are currently invested in financial products based on MVIS Indices. MVIS is a VanEck company. Contacts Nibha Ritter, MV Index Solutions +49 (0)69 4056 695 22 media-enquiries@mvis-indices.com
-
Centre for Quantum Technologies (CQT) Hands Over Satellite Operations of SpooQy-1 CubeSat to SpeQtral
SINGAPORE--(BUSINESS WIRE)--#QKD--SpeQtral announced today that it has taken over operations of the SpooQy-1 nanosatellite on behalf of the Centre for Quantum Technologies (CQT) at the National University of Singapore. SpooQy-1 is a shoebox-sized, 3U CubeSat hosting a quantum payload developed at CQT. It was launched April 2019 and subsequently deployed from the International Space Station on 17 June 2019. The quantum payload is the world’s first entangled photon source compact enough to fit on a CubeSat and qualified for the harsh space environment. The primary objective of the SpooQy-1 mission is to produce and characterize entangled photon pairs in space such that they violate the CHSH (Clauser-Horne-Shimony-Holt) Bell’s inequality. This is a core capability for future quantum communication networks. The CQT team is analysing scientific data from the mission and expects to publish results on the source’s performance in 2020. In the meantime, CQT and SpeQtral have signed an agreement allowing SpeQtral to manage ongoing operations. Formed as a spin-out company to commercialize quantum communications technologies developed at CQT, SpeQtral will monitor the long-term performance of the quantum payload for radiation damage and other degradation effects in the space environment. This information will help guide the development of long-lived quantum systems in space, necessary for the commercial deployment of space-based QKD systems. “Establishing a partnership for the SpooQy mission plays to all our strengths: at the Centre for Quantum Technologies, we will concentrate on scientific objectives, while SpeQtral focuses on commercial applications,” says Artur Ekert, Director of CQT. “SpooQy-1 is pioneering quantum technologies for space-based quantum key distribution (QKD) systems,” said Chune Yang Lum, co-founder and CEO of SpeQtral, “Being involved in this mission gives SpeQtral know-how that serves our goal of delivering next-generation secure communication networks.” About SpeQtral SpeQtral is developing space-based, quantum communication built on technologies developed at the Centre for Quantum Technologies (CQT) at the National University of Singapore. The team has developed technologies that harness the unique properties of quantum physics to enable encryption methods that can secure communications with forward security. SpeQtral is the only team with heritage from a successful on-orbit demonstration of a quantum light source on a CubeSat, and is committed to bringing future-proof security to the commercial world. Learn more at www.speqtral.space. About Centre for Quantum Technologies The Centre for Quantum Technologies (CQT) is a national Research Centre of Excellence in Singapore. It brings together physicists, computer scientists and engineers to do basic research on quantum physics and to build devices based on quantum phenomena. Experts in this new discipline of quantum technologies are applying their discoveries in computing, communications and sensing. The Centre was established in December 2007 with support from Singapore’s National Research Foundation and Ministry of Education. CQT is hosted by the National University of Singapore and also has staff at Nanyang Technological University. Learn more at www.quantumlah.org. Contacts SpeQtralMr. Chune Yang Lum info@speqtral.space@SpeQtral_Space Centre for Quantum TechnologiesMs. Jenny Hogan jenny.hogan@nus.edu.sg@quantumlah
-
Jason Industries Announces Sale of Metalex
MILWAUKEE--(BUSINESS WIRE)--Jason Industries, Inc. (NASDAQ:JASN, JASNW) (the "Company" or "Jason Industries") announced the successful completion of the sale of its Metalex business within the Engineered Components segment to UPG LLC (“UPG”) for approximately $5 million cash and assumption of certain liabilities, effective today. “The divestiture of Metalex further simplifies our portfolio to the remaining Osborn and Milsco businesses, Jason’s two pillars due to their market leadership, diverse sources of revenue and scalability,” said Brian Kobylinski, chairman and chief executive officer of Jason. “We thank our Metalex employees for their hard work and wish them continued success as part of the UPG organization.” The Metalex business being sold contributed approximately $39 million to Jason’s trailing twelve-month sales ending September 27, 2019. The Metalex operations in the United States and Mexico will be organized as a new subsidiary of UPG, and the approximately 200 employees will become employees of that subsidiary. UPG’s portfolio of companies offers best-in-class steel processing and production capabilities. The Company was advised on the transaction by BMO Capital Markets Corp. and Godfrey & Kahn, S.C.. The Metalex business will be reported within discontinued operations beginning in the fourth quarter of 2019. About Jason Industries, Inc. The Company is the parent company to a global family of manufacturing leaders within the finishing and seating markets, including Osborn (Richmond, Ind. and Burgwald, Germany) and Milsco (Milwaukee, Wis.). Headquartered in Milwaukee, Wis., Jason employs more than 2,200 people in 13 countries. To learn more, please visit www.jasoninc.com. Contacts Investor Relations Rachel Zabkowicz investors@jasoninc.com414.277.2007
-
Global Automated Blood Tube Labeler and Specimen Transport Box Market 2020-2024 | Evolving Opportunities with Avantor Inc. and Greiner AG | Technavio
LONDON--(BUSINESS WIRE)--#automatedbloodtubelabelerandspecimentransportbox--Technavio has been monitoring the global automated blood tube labeler and specimen transport box market, and the market is poised to grow by USD 94.57 million during 2020-2024 at a CAGR of over 7% during the forecast period. Request Free Sample Pages Read the 143-page research report with TOC on "Automated Blood Tube Labeler and Specimen Transport Box Market Analysis Report by Geography (Asia, Europe, North America, and ROW), by Product (Automated blood tube labeler and Specimen transport box), and Segment Forecasts, 2020-2024". The rising adoption of automated labeling devices over manual labeling of blood tubes minimizes the incidence of critical phlebotomy errors. Manual label making and tube labeling is not only time consuming but also a laborious process. The automated blood tube labelers eliminate the efforts of writing, prevent the wrinkling of labels, and improve the readability of information on the labels. These systems can handle several hundred tubes per hour with higher accuracy, precision, and consistency. Such benefits of automated labeling over manual labeling are expected to drive market growth during the forecast period. Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free. View market snapshot before purchasing Major Five Automated Blood Tube Labeler and Specimen Transport Box Market Companies: Avantor Inc. Avantor Inc. is headquartered in the US and operates the business under various segments such as Materials & Consumables, Equipment & Instrumentation, and Services & Specialty Procurement. The company offers an insulated, waterproof, and lightweight specimen transportation box. Brooks Automation, Inc. Brooks Automation Inc. is headquartered in the US and offers products through the following business units: Brooks Semiconductor Solutions Group and Brooks Life Sciences. The company provides a range of automated blood tube labelers. Cardinal Health Inc. Cardinal Health Inc. is headquartered in the US and operates under various business segments, namely Pharmaceutical and Medical. The company offers specimen transport boxes and heavy-duty specimen boxes. Greiner AG Greiner AG is headquartered in Austria and offers products through the following business segments: Greiner Packaging International GmbH, Greiner Bio-One International GmbH, Greiner Foam International GmbH, and Greiner Extrusion Group GmbH. The company offers sample transportation boxes and VACUETTE Transport Boxes. Inpeco SA Inpeco SA is headquartered in Switzerland and offers products through its business segment, Laboratory automation. The company provides a desktop reader unit, the ProTube Station. Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Automated Blood Tube Labeler and Specimen Transport Box Product Outlook (Revenue, USD Million, 2020-2024) Automated blood tube labeler Specimen transport box Automated Blood Tube Labeler and Specimen Transport Box Regional Outlook (Revenue, USD Million, 2020-2024) Asia Europe North America ROW Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report Related Reports on Health Care include: Blood Viscometer Market – Global Blood Viscometer Market by end-user (hospitals, diagnostic laboratories, and others) and geography (Americas, APAC, and EMEA). Blood Cancer Therapeutics Market – Global Blood Cancer Therapeutics Market by type (leukemia, lymphoma, and myeloma) and geography (Asia, Europe, North America, and ROW). About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: media@technavio.comWebsite: https://www.technavio.com
-
Bio-Rad Makes Progress Recovering from Recent Ransomware Attack
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) a global leader of life science research and clinical diagnostic products, today announced that the Company is making good progress recovering from a ransomware attack that was detected on Bio-Rad’s network on December 5, 2019. Once the malicious software was detected, Bio-Rad immediately took certain systems offline as part of its comprehensive response to contain the activity. The Bio-Rad website and telephone communications have been brought back online. Bio-Rad is continuing to restore affected systems and return to normal operations and the Company has resumed taking orders and shipping product. Our global ERP system was not affected by the attack, and we have found no evidence of unauthorized access, transfer, or misuse of data or personal information. “We appreciate the patience and understanding of our customers as we work to re-establish our systems following this attack,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer. “I would like to recognize the incredible work of Bio-Rad employees around the world this past week and commend their outstanding efforts to minimize disruption to our customers as we navigated this situation.” About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit www.bio-rad.com. This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding the recent ransomware attack. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “continue,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “believe,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements are based on current expectations and assumptions of the company and involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements. Contacts Bio-Rad Laboratories, Inc. Tina Cuccia, Corporate Communications 510-724-7000 tina_cuccia@bio-rad.com
-
Link Media Holdings CEO Announcement: James A. (Jim) McLaughlin to Retire; Scott LaFoy Appointed as Interim CEO
ROSWELL, Ga.--(BUSINESS WIRE)--Link Media Holdings, LLC (“Link”), a wholly owned subsidiary of Boston Omaha Corporation (NASDAQ:BOMN), today announced that CEO James A. (Jim) McLaughlin has decided to retire from the company effective January 1, 2020. Scott LaFoy, currently serving as the Head of Mergers and Acquisitions at Link, will be taking over as the Interim CEO. Jim will remain engaged in a consulting role through the first quarter of 2020 to assist with the transition. Mr. McLaughlin joined Link in March of 2017 and has guided the company through three years of rapid growth, more than quintupling the number of billboard faces over this three-year period and making Link a leading outdoor advertising company in the U.S. Prior to joining Link, Mr. McLaughlin operated several major outdoor advertising companies for various investor groups over his more than 46-year career. Link has begun the search for its next permanent CEO and, in addition to Mr. LaFoy, will also consider selected external eligible candidates before making a final hire. Mr. LaFoy has more than three decades of experience in the billboard industry and joined Link in May 2018. Mr. LaFoy spent 14 years building and operating his own billboard company, LaFoy Outdoor Advertising before selling it to Fairway in 2015. “Link Media Outdoor is a profitable, scaled business because of the tireless work of Jim and the team he has assembled. Adam and I are tremendously appreciative of the job Jim has done and we wish him all the best for his well-earned retirement,” said Boston Omaha Co-CEO and Co-Chairman, Alex Rozek. Mr. McLaughlin stated, “I turn 70 in a few weeks, and I’ve been working hard since I was 13 years old. I look forward to spending time with family and friends. A huge ‘thank you’ to Adam Peterson, Alex Rozek and Josh Weisenburger for the opportunity. It has been exciting, fun, and a blast building and running one of these companies one last time.” Link Media Outdoor operates approximately 5,600 billboard advertising faces in Georgia, Alabama, Florida, Wisconsin, West Virginia, Virginia, Illinois, Iowa, Missouri, Nebraska and Kansas. For more information visit www.linkmediaoutdoor.com. Forward-Looking Statements Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. Boston Omaha Corporation desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections. Contacts Boston Omaha Corporation Catherine Vaughan 617-875-8911 cathy@bostonomaha.com
-
General American Investors Announces Issue Price for the 2019 Year-End Dividend and Distribution Payable on December 30, 2019
NEW YORK--(BUSINESS WIRE)--General American Investors Company, Inc. (NYSE: GAM), a closed-end investment company, announced that the price at which shares of its common stock will be issued to stockholders who elected to receive additional shares in payment of the 2019 year-end dividend and distribution on its common stock will be $36.78 per share. The issue price represents the average between the high and the low prices on the New York Stock Exchange on December 13, 2019, which was below the net asset value of $42.73 per share on that date. The dividend and distribution is payable on December 30, 2019. As announced on November 6, the dividend and distribution amounts to $2.45 per share in the aggregate and is estimated to consist of: A distribution of $2.08 per share from net long-term capital gains on securities sold. A dividend of $0.37 per share from estimated undistributed net investment income for the full year 2019. The final determination as to the taxability of the above amounts will be reported to you in January 2020 via Form 1099-DIV. General American Investors was founded in 1927, has been publicly traded since its inception, and has been listed on the NYSE since 1930. The objective of the Company is long-term capital appreciation through investment in companies with above average growth potential. As of November 30, 2019, the Company had net assets of approximately $1.0 billion applicable to its 24.1 million shares of common stock outstanding. Its preferred shares (symbol GAM Pr B) are also listed on the NYSE and their aggregate liquidation value is $190.1 million. Contacts Eugene S. Stark Vice-President, Administration (212) 916-8447
